Measures that would update FDA’s authorities fell by the wayside earlier this fall, but lawmakers are considering the year-end spending deal to get them passed.
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.
